Cargando…

Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction

Pulmonary arterial hypertension (PAH) is commonly associated with connective tissue diseases (CTDs) including systemic sclerosis and systemic lupus erythematosus (SLE). The prevalence of PAH in SLE is estimated to be 0.5% to 17.5%. The pathophysiology of PAH involves multiple mechanisms from vasculi...

Descripción completa

Detalles Bibliográficos
Autor principal: Dhala, Atiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318206/
https://www.ncbi.nlm.nih.gov/pubmed/22489252
http://dx.doi.org/10.1155/2012/854941
_version_ 1782228679588315136
author Dhala, Atiya
author_facet Dhala, Atiya
author_sort Dhala, Atiya
collection PubMed
description Pulmonary arterial hypertension (PAH) is commonly associated with connective tissue diseases (CTDs) including systemic sclerosis and systemic lupus erythematosus (SLE). The prevalence of PAH in SLE is estimated to be 0.5% to 17.5%. The pathophysiology of PAH involves multiple mechanisms from vasculitis and in-situ thrombosis to interstitial pulmonary fibrosis which increases pulmonary vascular resistance, potentially leading to right heart failure. Immune and inflammatory mechanisms may play a significant role in the pathogenesis or progression of PAH in patients with CTDs, establishing a role for anti-inflammatory and immunosuppressive therapies. The leading predictors of PAH in SLE are Raynaud phenomenon, anti-U1RNP antibody, and anticardiolipin antibody positivity. The first-line of diagnostic testing for patients with suspected SLE-associated PAH (SLE-aPAH) involves obtaining a Doppler echocardiogram. Once the diagnosis is confirmed by right heart catheterization, SLE-aPAH patients are generally treated with oxygen, anticoagulants, and vasodilators. Although the prognosis and therapeutic responsiveness of these patients have improved with the addition of intensive immunosuppressive therapies, these treatments are still largely unproven. Recent data put the one-year survival rate for SLE-aPAH patients at 94%. Pregnant women are most at risk of dying due to undiagnosed SLE-aPAH, and screening should be considered essential in this population.
format Online
Article
Text
id pubmed-3318206
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33182062012-04-09 Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction Dhala, Atiya Clin Dev Immunol Review Article Pulmonary arterial hypertension (PAH) is commonly associated with connective tissue diseases (CTDs) including systemic sclerosis and systemic lupus erythematosus (SLE). The prevalence of PAH in SLE is estimated to be 0.5% to 17.5%. The pathophysiology of PAH involves multiple mechanisms from vasculitis and in-situ thrombosis to interstitial pulmonary fibrosis which increases pulmonary vascular resistance, potentially leading to right heart failure. Immune and inflammatory mechanisms may play a significant role in the pathogenesis or progression of PAH in patients with CTDs, establishing a role for anti-inflammatory and immunosuppressive therapies. The leading predictors of PAH in SLE are Raynaud phenomenon, anti-U1RNP antibody, and anticardiolipin antibody positivity. The first-line of diagnostic testing for patients with suspected SLE-associated PAH (SLE-aPAH) involves obtaining a Doppler echocardiogram. Once the diagnosis is confirmed by right heart catheterization, SLE-aPAH patients are generally treated with oxygen, anticoagulants, and vasodilators. Although the prognosis and therapeutic responsiveness of these patients have improved with the addition of intensive immunosuppressive therapies, these treatments are still largely unproven. Recent data put the one-year survival rate for SLE-aPAH patients at 94%. Pregnant women are most at risk of dying due to undiagnosed SLE-aPAH, and screening should be considered essential in this population. Hindawi Publishing Corporation 2012 2012-03-22 /pmc/articles/PMC3318206/ /pubmed/22489252 http://dx.doi.org/10.1155/2012/854941 Text en Copyright © 2012 Atiya Dhala. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Dhala, Atiya
Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction
title Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction
title_full Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction
title_fullStr Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction
title_full_unstemmed Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction
title_short Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction
title_sort pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318206/
https://www.ncbi.nlm.nih.gov/pubmed/22489252
http://dx.doi.org/10.1155/2012/854941
work_keys_str_mv AT dhalaatiya pulmonaryarterialhypertensioninsystemiclupuserythematosuscurrentstatusandfuturedirection